摘要
透明质酸(HA)是一种相对较新的药物传递系统的结构。CD44和HA运动介导的受体在内吞作用时发挥关键作用。通过利用HA作为药物载体,细胞摄取和肿瘤靶向给药的效率可以增加。目前,HA为物理封装或与各种药物化学共轭提供了有效的平台。在这篇综述中,我们总结了HA最新的研究进展,并对基于HA药物输送系统的应用前景进行了讨论。
关键词: CD44,化学改性,偶联物,衍生物,透明质酸,纳米载体。
图形摘要
Current Drug Targets
Title:Advances in Hyaluronic Acid-Based Drug Delivery Systems
Volume: 17 Issue: 6
Author(s): Yan Jiao, Xin Pang and Guangxi Zhai
Affiliation:
关键词: CD44,化学改性,偶联物,衍生物,透明质酸,纳米载体。
摘要: Hyaluronic acid (HA) is a relatively new polymer for the construction of drug delivery systems. CD44 and the receptor for HA-mediated motility play a key role in vivo for the receptormediated endocytosis of HA. Cellular uptake and the efficiency of tumor-targeted drug delivery are supposed to increase through utilizing HA as drug carriers. Currently, HA has provided a promising platform to physically encapsulate or chemically conjugate with various drugs. In this review, we presented the most latest advances in HA-based drug delivery systems and some forward-looking ideas are discussed.
Export Options
About this article
Cite this article as:
Yan Jiao, Xin Pang and Guangxi Zhai , Advances in Hyaluronic Acid-Based Drug Delivery Systems, Current Drug Targets 2016; 17 (6) . https://dx.doi.org/10.2174/1389450116666150531155200
DOI https://dx.doi.org/10.2174/1389450116666150531155200 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Proliferation of ECV304 Cells by a Disintegrin from Chinese Green Tree Viper
Protein & Peptide Letters Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Preclinical Investigation of Radiopharmaceuticals: An Accurate and Multidisciplinary Approach
Current Radiopharmaceuticals Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Recent Patents on Biotechnology Anal Carcinoma
Current Cancer Therapy Reviews The Yin and Yang of microRNA Assay Methods
MicroRNA Targeting the Nucleotide Metabolism Proteins of the NUDIX Family and SAMHD1 in Cancer
Current Medicinal Chemistry Inhibitors of the Hedgehog Signal Transduction Pathway
Current Cancer Therapy Reviews Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Current Bioactive Compounds Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Morphometric Analysis of Eukaryotic Cells
Recent Patents on Medical Imaging Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story
Current Medicinal Chemistry - Anti-Cancer Agents Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents